Alterity Therapeutics (ASX:ATH) received fast-track designation from the US Food and Drug Administration for ATH434 for the potential treatment of multiple system atrophy, according to a Monday filing with the Australian bourse.
Multiple system atrophy is a progressive neurodegenerative disorder affecting both the central and autonomic nervous systems.
This designation aims to expedite the development and review of new investigational products, the filing said.
Shares were up 11% in morning trade on Monday.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.